Abstract
There is irrefutable evidence that ovarian hormones are intimately involved in the genesis of breast cancer and the protective effect of early menopause has been well documented. Natural menopause occurring before age 45 is associated with one-half the breast cancer risk of menopause occurring after age 55 [1]. Early artificial menopause has a similar effect.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Trichopoulos, D., MacMahon, B., Cole, P. (1972). Menopause and breast cancer risk. J. Natl. Cancer Inst., 48, 605–613.
Feinleib, M. (1968). Breast cancer and artificial menopause: a cohort study. J. Natl. Cancer Inst., 41, 315–329.
Hirayama, T., Wynder, E.L. (1962). A study of the epidemiology of cancer of the breast II. The influence of hysterectomy. Cancer, 15, 28–38.
Brinton, L.A., Schairer, C., Hoover, R.N. (1988). Menstrual factors and risk of breast cancer. Cancer Invest., 6, 245–254.
Tobacman, J., Tucker, M., Kase, R. et al. (1982). Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet, ii, 795–797.
Cruickshank, D., Haites, N. et al. (1992) The multidisciplinary management of a family with epithelial ovarian cancer. Br. J. Obstet. Gynaecol., 99, 226–231.
Pike, M.C., Ross, R.K., Lobo, R.A. et al. (1989). LHRH agonists and the prevention of breast and ovarian cancer. Br. J. Cancer, 60, 142–148.
Spicer, D.V., Shoupe, D., Pike, M. (1991). GnRH agonists as contraceptive agents: Predicted significantly reduced risk of breast cancer. Contraception, 44,289–310.
Friedman, A., Rein, M., Harrison-Atlas, D., Garfield, J., Doubilet, P. (1989). A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil. Steril., 52, 728–733.
Schlaff, W., Zerhouni, E., Huth, J. et al. (1989). A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (Leuprolide) in the treatment of uterine leiomyomata.Obstet. Gynecoi, 74, 856–862.
Pike, M.C., Spicer, D.V., Dahmoush, L., Press, M.F. (1993). Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. Epidemiol. Rev., 15,17–35.
Stanford, J., Thomas, D. (1993). Exogenous progestins and breast cancer. Epidemiol. Rev., 15, 98–107.
Schiff, I., Sela, H., Cramer, D., Tulchinsky, D., Ryan, K. (1982). Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril., 37, 79–82.
Studd, J., Thom, M., Paterson, M. (1980). The prevention and treatment of endometrial pathology in postmenopausal women receiving exogenous oestrogens. In Pasetto, W., Pavletti, R., Lambrus, J. (eds.), The Menopause and Postmenopause, MTP Press, Lancaster, England, 127–138.
Whitehead, M., Lane, G., Siddle, N., Townsend, P., King, R. (1983). Avoidance of endometrial hyperstimulation in estrogen-treated postmenopausal women. Semin. Reprod. Endocrin., 1, 41–54.
Spicer, D.V., Pike, M.C., Pike, A. et al. (1993). Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception, 47,427–444.
Henderson, B., Ross, R., Lobo, R., Pike, M., Mack, T. (1988). Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril., 49, (Suppl.), 9–15.
Spicer, D., Ursin, G., Parisky, Y. et al. (1994). Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J. Natl. Cancer Inst., 86, 431–436.
Saftlas, A.F., Szklo, M. (1987). Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev., 9, 146–74.
Warner, E., Lockwood, G. (1992). The risk of breast cancer associated with mammographic parenchymal patterns: a meta -analysis of the published literature to examine the effect of method of classification. Cancer Detect. Prev., 16, 67–72.
Key, T.J.A., Pike, M.C. (1988). The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br. J. Cancer, 57, 205–212.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Spicer, D.V., Krecker, E.A., Pike, M.C. (1995). Trial of Ovarian Suppression for Protection. In: Stoll, B.A. (eds) Reducing Breast Cancer Risk in Women. Developments in Oncology, vol 75. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0489-0_13
Download citation
DOI: https://doi.org/10.1007/978-94-011-0489-0_13
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4219-2
Online ISBN: 978-94-011-0489-0
eBook Packages: Springer Book Archive